The EV skincare market grew faster than the standards needed to evaluate it. Clinics are increasingly asked to make procurement and prescribing decisions about products labelled "exosome" or "EV" with no shared scientific framework for separating substantiated products from labels. The criteria below are the five questions every clinician should ask before stocking an EV product. Each one is a specific data point. None of them are negotiable.
These criteria are also the structure of BioThera's free EV SELECT GUIDE, which goes deeper on each one and includes a printable evaluation worksheet. The framework here is the short form.
1. Source
What cell type, tissue, organism, or plant species are the EVs derived from? This is the first question because it determines almost everything else about the product. EVs from human stem cells, platelet-rich plasma, adipose tissue, plant cells, and microbial sources all carry different molecular cargo and act through different mechanisms. They are biologically incomparable. A product that does not name its source clearly, beyond a generic "exosome" label, has not given you the information you need.
Look for the species, the tissue or biomass, and ideally the strain or cultivar. "Plant-derived" is not specific enough. "Aloe barbadensis leaf" is. The same applies to mammalian sources: "stem cell-derived" is not specific enough; "human umbilical cord mesenchymal stem cell" is.
2. Particle concentration
Is there a verified particles-per-millilitre figure, and is the analytical method named?
The gold standard for particle counting under MISEV2023 is Nanoparticle Tracking Analysis (NTA), which measures individual particles in suspension and reports both concentration and size distribution. A credible product specifies its particle count as an NTA-verified figure with a stated lower bound, on a per-batch basis, not as a marketing range or a "representative lot" figure.
Products that do not disclose particle concentration at all should be considered uncharacterized. There is no way to dose them and no way to compare them to alternatives. The absence of this number is a signal, not a stylistic choice.
3. Certificate of Analysis
Is batch-specific documentation available, or is the same CoA recycled across all production runs?
A credible EV CoA documents at minimum: NTA-verified particle concentration with a stated particles/mL figure (not a range), particle size distribution including mean and mode diameter, purity indicators such as particle-to-protein ratio, a safety panel covering sterility and endotoxin / LPS screening, and source plus batch traceability identifying the production run the data corresponds to.
The phrase to watch for is "representative lot." A representative-lot CoA is not a quality document. It is a sample of one batch held up as evidence about all batches, which is exactly the opposite of what batch verification means. BioThera issues batch-specific CoAs. Any credible manufacturer should.
4. Isolation method
Is the production process disclosed, even at the level of which method family was used?
Isolation method directly shapes the final EV preparation. Ultracentrifugation, ultrafiltration, size exclusion chromatography, and precipitation all yield preparations with different purity profiles, different size distributions, different surface protein compositions, and different biological activities. Two products from the same source isolated by different methods are not the same product.
Not every manufacturer can disclose every detail of a proprietary process publicly, and that is reasonable. What is not reasonable is "we cannot tell you anything." A credible manufacturer can tell you the method family and provide process transparency documentation under appropriate agreement to qualified clinical and manufacturing partners. Process secrecy is a supplements-industry norm with no place in characterized EV manufacturing.
5. Cold chain
EVs are thermolabile biological particles. They lose biological activity under elevated temperatures, freeze-thaw cycles outside specification, and prolonged storage at uncontrolled conditions.
A credible EV product specifies storage temperature, ships under controlled-temperature conditions, and provides clear in-clinic and patient-side handling instructions. A product shipped at ambient temperature with no temperature monitoring is, at best, untested under realistic logistics. At worst, it is biologically degraded by the time it reaches the consultation room.
For procurement teams, ask about temperature monitoring during shipment, recommended storage conditions, and shelf life under those conditions. The answers should be specific.
What the framework rules out
Apply the five criteria to a typical "exosome" cosmetic product on the market today and a clear pattern emerges. Source is often vague. Particle concentration is undisclosed or stated without methodology. CoAs are either absent or "representative." Isolation method is treated as a trade secret with no qualified-partner disclosure path. Cold chain is rarely specified.
That is not a quality EV product. It is a label using EV vocabulary without the underlying characterization. The framework above is how clinicians draw that line.
What it lets in
A characterized EV preparation, by contrast, will answer all five questions specifically. Named source. NTA-verified particle count with a lower bound. Batch-specific CoA available. Isolation method disclosed at the family level with deeper transparency under partner agreement. Cold-chain protocol stated.
That set of answers is what BioThera's mPDEV Serum was built to deliver and what we expect any credible peer EV manufacturer to be able to match. The criteria are not a competitive advantage. They are a baseline.
For the deeper version of this framework, including a printable evaluation worksheet for use during product audits, the EV SELECT GUIDE is available free to clinicians on the Resources page.